双主业协同发力 尔康制药上半年净利润同比增长近5倍

Core Viewpoint - Hunan Erkang Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a revenue of 680 million yuan, a year-on-year increase of 9.74%, and a net profit of 37.63 million yuan, reflecting a substantial year-on-year growth of 497.36% [1] Pharmaceutical Sector - The company is focusing on innovation and international development, successfully entering the African market with a new production project in Tanzania, involving an investment of 10 million USD to upgrade local facilities for solid dosage forms [1] - The company has achieved significant milestones in its pharmaceutical sector, including the successful evaluation of its Vitamin B6 injection for consistency and obtaining a drug registration certificate for theobromine injection [1] New Energy Materials Sector - The new energy materials segment generated revenue of 127 million yuan, accounting for 18.57% of total revenue, establishing itself as a crucial business support and second growth curve for the company [2] - The company has improved operational efficiency at its Nigerian mining facility, enhancing daily processing capacity and lithium recovery rates [2] Future Outlook - The company plans to continue focusing on its core strategies, consolidating domestic advantages while accelerating the development of its pharmaceutical and new energy businesses in Africa, aiming to optimize talent structure and operational efficiency to achieve annual business goals [2]